Literature DB >> 25552681

Radotinib in the treatment of chronic phase chronic myeloid leukemia patients.

Ahmet Emre Eskazan1, Teoman Soysal2.   

Abstract

Entities:  

Keywords:  chronic myeloid leukemia; imatinib; radotinib; tyrosine kinase inhibitor

Mesh：

Substances：

Year:  2015        PMID： 25552681      PMCID： PMC4281335          DOI： 10.3324/haematol.2014.117846

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.

Authors:  Jorge E Cortes; Hagop M Kantarjian; Tim H Brümmendorf; Dong-Wook Kim; Anna G Turkina; Zhi-Xiang Shen; Ricardo Pasquini; H Jean Khoury; Steven Arkin; Angela Volkert; Nadine Besson; Richat Abbas; Junyuan Wang; Eric Leip; Carlo Gambacorti-Passerini
Journal:  Blood       Date:  2011-08-24       Impact factor: 22.113

2.  Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.

Authors:  Andreas Hochhaus; Hagop M Kantarjian; Michele Baccarani; Jeffrey H Lipton; Jane F Apperley; Brian J Druker; Thierry Facon; Stuart L Goldberg; Francisco Cervantes; Dietger Niederwieser; Richard T Silver; Richard M Stone; Timothy P Hughes; Martin C Muller; Rana Ezzeddine; Athena M Countouriotis; Neil P Shah
Journal:  Blood       Date:  2006-11-30       Impact factor: 22.113

3.  Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.

Authors:  Neil P Shah; Dong-Wook Kim; Hagop Kantarjian; Philippe Rousselot; Pedro Enrique Dorlhiac Llacer; Alicia Enrico; Jorge Vela-Ojeda; Richard T Silver; Hanna Jean Khoury; Martin C Müller; Alexandre Lambert; Yousif Matloub; Andreas Hochhaus
Journal:  Haematologica       Date:  2010-02       Impact factor: 9.941

4.  Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.

Authors:  Sung-Hyun Kim; Hari Menon; Saengsuree Jootar; Tapan Saikia; Jae-Yong Kwak; Sang-Kyun Sohn; Joon Seong Park; Seong Hyun Jeong; Hyeoung Joon Kim; Yeo-Kyeoung Kim; Suk Joong Oh; Hawk Kim; Dae Young Zang; Joo Seop Chung; Ho Jin Shin; Young Rok Do; Jeong-A Kim; Dae-Young Kim; Chul Won Choi; Sahee Park; Hye Lin Park; Gong Yeal Lee; Dae Jin Cho; Jae Soo Shin; Dong-Wook Kim
Journal:  Haematologica       Date:  2014-04-04       Impact factor: 9.941

5.  Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.

Authors:  Ahmet Emre Eskazan; Deniz Eyice; Enes Ali Kurt; Tugrul Elverdi; Fevzi Firat Yalniz; Ayse Salihoglu; Muhlis Cem Ar; Seniz Ongoren Aydin; Zafer Baslar; Burhan Ferhanoglu; Yildiz Aydin; Nukhet Tuzuner; Ugur Ozbek; Teoman Soysal
Journal:  Leuk Res       Date:  2014-04-18       Impact factor: 3.156

Review 6.  Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

Authors:  E Jabbour; M Deininger; A Hochhaus
Journal:  Leukemia       Date:  2010-09-23       Impact factor: 11.528

7.  Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.

Authors:  Hagop M Kantarjian; Francis J Giles; Kapil N Bhalla; Javier Pinilla-Ibarz; Richard A Larson; Norbert Gattermann; Oliver G Ottmann; Andreas Hochhaus; Jerald P Radich; Giuseppe Saglio; Timothy P Hughes; Giovanni Martinelli; Dong-Wook Kim; Yaping Shou; Neil J Gallagher; Rick Blakesley; Michele Baccarani; Jorge Cortes; Philipp D le Coutre
Journal:  Blood       Date:  2010-11-22       Impact factor: 22.113

8.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Authors:  Hagop M Kantarjian; Francis Giles; Norbert Gattermann; Kapil Bhalla; Giuliana Alimena; Francesca Palandri; Gert J Ossenkoppele; Franck-Emmanuel Nicolini; Stephen G O'Brien; Mark Litzow; Ravi Bhatia; Francisco Cervantes; Ariful Haque; Yaping Shou; Debra J Resta; Aaron Weitzman; Andreas Hochhaus; Philipp le Coutre
Journal:  Blood       Date:  2007-08-22       Impact factor: 22.113

Review 9.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113
  9 in total
  2 in total

Review 1.  Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update.

Authors:  Ahmet Emre Eskazan; Dilek Keskin
Journal:  Ther Adv Hematol       Date:  2017-07-25

2.  Development and validation of analytical method for the determination of radotinib in human plasma using liquid chromatography-tandem mass spectrometry.

Authors:  Hyo-Bum Seo; Seungil Cho; Young-Ran Yoon; Dong-Seok Yim
Journal:  Transl Clin Pharmacol       Date:  2017-12-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.